Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment

被引：0
|
作者：
Babic, I [1 ,2 ,3 ]
Gorak, A. [1 ,2 ]
Hughes, J. [2 ]
Engel, M. [2 ]
Sellers, D. [1 ,2 ]
Else, P. [2 ]
Lufe, L. [1 ,2 ]
Obeid, A. L. [1 ,2 ]
Osborne, A. L. [1 ,2 ]
Le Mesurier, P. [1 ,2 ]
Pai, N. [2 ,3 ]
Huang, X. F. [1 ,2 ]
Weston-Green, K. [1 ,2 ]
机构：
[1] Univ Wollongong, Ctr Translat Neurosci, Wollongong, NSW 2522, Australia
[2] Illawarra Hlth & Med Res Inst, Wollongong, NSW 2522, Australia
[3] Illawarra Shoalhaven Local Hlth Dist, Wollongong, NSW 2500, Australia
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM426
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [41] Aspiration risk with glucagon-like peptide 1 (GLP-1) agonists
    Marroquin-Harris, M.
    Olesnicky, B.
    ANAESTHESIA, 2023, 78 (12) : 1524 - 1524
  • [42] Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
    Sawada, Noritaka
    Adachi, Kei
    Nakamura, Nobuhisa
    Miyabe, Megumi
    Ito, Mizuho
    Kobayashi, Shuichiro
    Miyajima, Shin-ichi
    Suzuki, Yuki
    Kikuchi, Takeshi
    Mizutani, Makoto
    Toriumi, Taku
    Honda, Masaki
    Mitani, Akio
    Matsubara, Tatsuaki
    Naruse, Keiko
    JOURNAL OF DIABETES RESEARCH, 2020, 2020
  • [43] Lack of "memory effect" for insulinotropic actions of glucagon-like peptide 1 (GLP-1)
    Nauck, MA
    Meier, S
    Holst, JJ
    Hücking, K
    Ritzel, R
    Schmiegel, WH
    DIABETES, 2000, 49 : A227 - A227
  • [44] THE COLON AS A SOURCE FOR GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
    HOLST, JJ
    OLESEN, KM
    GUDMANDHOYER, E
    DEACON, CF
    HANSEN, CP
    JOHNSEN, AH
    MIHOLIC, J
    NAUCK, M
    QUALMANN, C
    DIABETOLOGIA, 1995, 38 : A170 - A170
  • [45] The effect of glucagon-like peptide 1 (GLP-1) on insulin in diabetic dogs.
    Giacca, A
    Sandhu, H
    Wiesenthal, S
    McCall, RH
    Tchipachvili, V
    Shi, ZQ
    Vranic, M
    Efendic, S
    DIABETOLOGIA, 1997, 40 : 1050 - 1050
  • [46] Glucagon-like peptide (GLP-1) in the developing lung.
    Jia, X
    Okazawa, M
    FASEB JOURNAL, 1996, 10 (03): : 149 - 149
  • [47] Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease
    Glotfelty, Elliot J.
    Olson, Lars
    Karlsson, Tobias E.
    Li, Yazhou
    Greig, Nigel H.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (06) : 595 - 602
  • [48] Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
    Kopp, Katherine O.
    Glotfelty, Elliot J.
    Li, Yazhou
    Greig, Nigel H.
    PHARMACOLOGICAL RESEARCH, 2022, 186
  • [49] Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
    Jiang, Neng
    Jing, Lin
    Li, Qing
    Su, Sibiao
    Yang, Qimeng
    Zhou, Feng
    Chen, Xinyu
    Han, Jing
    Tang, Chunli
    Tang, Weizhong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 212
  • [50] IDENTIFICATION ON PREVENTIVE MECHANISM OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONIST FOR ATHEROSCLEROSIS MODEL
    Lee, S. -G.
    Kim, J. -S.
    Lee, H. -J.
    Lee, S. -J.
    Oh-Hyun, L.
    Kim, C. -K.
    ATHEROSCLEROSIS, 2023, 379
12345